Navigation Links
Lanx®, Inc. Announces 17,000 Aspen™ Spinous Process Fixation Devices Implanted
Date:4/11/2011

BROOMFIELD, Colo., April 11, 2011 /PRNewswire/ -- Lanx®, Inc., a privately held medical device company focused on developing and commercializing innovative devices for spinal surgery, today announced it has reached 17,000 implantations of its flagship product, the Aspen™ Spinous Process Fixation System (Aspen), at the 2011 American Association of Neurological Surgeons (AANS) Annual Meeting, Denver, CO.

"This significant implant milestone is evidence that the Aspen system is gaining mainstream industry acceptance and solidifies Lanx's leadership position in the spinous process fixation market," said Dan Gladney, Chief Executive Officer, Lanx. "As the core product in our comprehensive fusion portfolio, the success of the Aspen system is a significant accomplishment for Lanx. We plan to leverage its momentum and expand the platform to include enhancements that will better fit patient anatomies, further simplify the procedure and address new clinical applications."

Over 700 spine surgeons have used the Aspen system to provide spinous process fixation as a less invasive alternative to pedicle screws. The system includes a proprietary spiked fixation plate designed to be rigidly affixed to the spinous process with the use of customized surgical instrumentation. The unique central barrel allows the device to share significant weight load required in the lumbar and thoracic spine, while its hollow and fenestrated design serves as a bone graft containment chamber to promote fusion.

"I began using the Aspen device almost three years ago and have been pleased with the fixation and, most importantly, patient outcomes compared to that of pedicle screws," said Ronald Sabbagh, M.D., fellowship-trained spine surgeon at Beebe Medical Center in Lewes, DE. "I have also realized a significant reduction in tissue trauma, bone disruption and noticeably less blood loss when using the Aspen system compared to pedicle screws, which I believe is translating to shorter hospital stays, quicker recovery times and less post-operative pain for my fusion patients."

The Aspen system is intended for single level use in the thoracic or lumbar spine (T1-S1) for the treatment of degenerative disc disease, spondylolisthesis, spinal trauma or spinal tumor. The Aspen system is currently being used in a wide range of surgical applications including posterior fusions and interbody fusions (TLIF, ALIF and Lateral).

Lanx markets a full line of spine technologies that will be on display at the Lanx AANS booth #1016.

For more information about the Aspen system or Lanx, please visit www.lanx.com.

About Lanx, Inc.Lanx is one of the largest and fastest growing privately held global spine companies. The Company was founded by a team of experienced medical device professionals and engineers in 2003 to improve the quality of spine care and provide surgeons with innovative products. Lanx develops and markets a full line of fusion technologies with a focus on minimally invasive and biologics products. The Company is headquartered in Broomfield, CO. More information on Lanx and its spinal surgery products can be found at www.lanx.com.Company Contact:

Media / Investors:Steve Deitsch

Kim Muscara / Nick LaudicoChief Financial Officer

(646) 536-7011/ 7030(303) 443-7500

kmuscara@theruthgroup.comsteve.deitsch@lanx.com

nlaudico@theruthgroup.com
'/>"/>

SOURCE Lanx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare Executives, ... honor of being selected as winners of multiple awards ... Executives Website at the PLATINUM level, Blue Zones Menu ... at the GOLD Level, and our proprietary 3ConneX Platform ... Simpson Healthcare Executives, we are excited to showcase our ...
(Date:12/2/2016)... BRUSSELS , Dec. 2, 2016  UCB is pleased to ... presentation at the upcoming 70 th American Epilepsy Society ... Houston, TX , USA. 1-12 ... safety and efficacy profile of VIMPAT ® (lacosamide) CV ... also share findings on the current state of the union ...
(Date:12/2/2016)... Dec. 2, 2016 Allergan plc (NYSE: ... information on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a ... the Company will repurchase $10 billion of its ordinary shares. ...
Breaking Medicine Technology:
(Date:12/2/2016)... Raleigh, NC (PRWEB) , ... December 02, 2016 , ... ... the Open Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare ... plan (Part C) or prescription drug plan (Part D) need to make changes during ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... inspirational interview of two ostomy patients, standing as living proof that attitude and ... from digestive diseases and issues that spike around the holidays. This campaign will ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... of "Cardiovascular Health" in USA Today, which covers the innovative treatments, therapeutic technologies, ... while maintaining fulfilling lives. “We are prolonging life 6 years in the last ...
(Date:12/2/2016)... OH (PRWEB) , ... December 02, 2016 , ... ... of veterinarian diagnostic imaging systems and the first company to offer ... With a Heart at their tradeshow booth # 941 for the American Association ...
(Date:12/2/2016)... ... 02, 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, ... into Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in ... the details line up exactly with Bible Prophecy – a protected way for those ...
Breaking Medicine News(10 mins):